Picture loading failed.

Anti-IL13;IL4 therapeutic antibody (Pre-made Romilkimab biosimilar,Bispecific Dual Variable Domain IG) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Romilkimab (SAR156597), however, “is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralizes IL-4/IL-13 making it ideal for exploration in fibrosis,” the researchers explain.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-492-1mg 1mg 3090
GMP-Bios-ab-492-10mg 10mg 21890
GMP-Bios-ab-492-100mg 100mg 148000
GMP-Bios-ab-492-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL13;IL4 therapeutic antibody (Pre-made Romilkimab biosimilar,Bispecific Dual Variable Domain IG)
INN Name Romilkimab
TargetIL13;IL4
FormatBispecific Dual Variable Domain IG
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2017
Year Recommended2018
CompaniesSanofi
Conditions Approvedna
Conditions ActiveSystemic scleroderma
Conditions DiscontinuedIdiopathic pulmonary fibrosis
Development Techna